Daiwa Securities Group Inc. Fate Therapeutics Inc Transaction History

Daiwa Securities Group Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$17.78 - $42.39 $1,440 - $3,433	81 Added 29.03%	360 $9,000
Q4 2021 Feb 03, 2022	SELL	$47.84 - $64.34 $2,248 - $3,023	-47 Reduced 14.42%	279 $16,000
Q3 2021 Nov 05, 2021	BUY	$59.27 - $95.73 $8,297 - $13,402	140 Added 75.27%	326 $19,000
Q1 2021 May 03, 2021	BUY	$72.16 - $117.4 $1,587 - $2,582	22 Added 13.41%	186 $15,000
Q4 2020 Feb 04, 2021	SELL	$38.09 - $100.95 $12,417 - $32,909	-326 Reduced 66.53%	164 $15,000
Q3 2020 Nov 02, 2020	BUY	$30.41 - $40.5 $2,432 - $3,240	80 Added 19.51%	490 $20,000
Q1 2019 Apr 26, 2019	SELL	$13.15 - $18.71 $1,841 - $2,619	-140 Reduced 25.45%	410 $7,000
Q4 2018 Feb 05, 2019	BUY	$11.48 - $16.98 $6,314 - $9,339	550 New	550 $7,000

166

101M

41.3K

15.9K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $138M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

Stay updated on Daiwa Securities Group Inc. with notifications on news.